...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Infection and immunity >NYVAC-Pf7: a poxvirus-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria.
【24h】

NYVAC-Pf7: a poxvirus-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria.

机译：NYVAC-Pf7：痘病毒载体的多抗原，多阶段恶性疟原虫疟疾候选疫苗。

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The highly attenuated NYVAC vaccinia virus strain has been utilized to develop a multiantigen, multistage vaccine candidate for malaria, a disease that remains a serious global health problem and for which no highly effective vaccine exists. Genes encoding seven Plasmodium falciparum antigens derived from the sporozoite (circumsporozoite protein and sporozoite surface protein 2), liver (liver stage antigen 1), blood (merozoite surface protein 1, serine repeat antigen, and apical membrane antigen 1), and sexual (25-kDa sexual-stage antigen) stages of the parasite life cycle were inserted into a single NYVAC genome to generate NYVAC-Pf7. Each of the seven antigens was expressed in NYVAC-Pf7-infected culture cells, and the genotypic and phenotypic stability of the recombinant virus was demonstrated. When inoculated into rhesus monkeys, NYVAC-Pf7 was safe and well tolerated. Antibodies that recognize sporozoites, liver, blood, and sexual stages of P. falciparum were elicited. Specific antibody responses against four of the P.falciparum antigens (circumsporozoite protein, sporozoite surface protein 2, merozoite surface protein 1, and 25-kDa sexual-stage antigen) were characterized. The results demonstrate that NYVAC-Pf7 is an appropriate candidate vaccine for further evaluation in human clinical trials.
机译：高度减毒的NYVAC痘苗病毒株已用于开发针对疟疾的多抗原，多阶段疫苗候选物，该疾病仍然是严重的全球健康问题，并且不存在针对其的高效疫苗。编码来自子孢子（环子孢子蛋白和子孢子表面蛋白2），肝脏（肝阶段抗原1），血液（裂殖子表面蛋白1，丝氨酸重复抗原和根尖膜抗原1）和有性（25）的七个恶性疟原虫抗原的基因将寄生虫生命周期的-kDa性阶段抗原）阶段插入单个NYVAC基因组中以产生NYVAC-Pf7。这七个抗原中的每一个均在感染NYVAC-Pf7的培养细胞中表达，并证明了重组病毒的基因型和表型稳定性。当将其接种到恒河猴中时，NYVAC-Pf7是安全且耐受性良好的。引发了识别恶性疟原虫子孢子，肝，血液和性阶段的抗体。表征了针对四种恶性疟原虫抗原（环子孢子蛋白，子孢子表面蛋白2，裂殖子表面蛋白1和25 kDa性期抗原）的特异性抗体反应。结果表明，NYVAC-Pf7是在人类临床试验中进一步评估的合适候选疫苗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号